Dynavax Technologies Corporation
Dynavax Technologies Corporation Fundamental Analysis
Dynavax Technologies Corporation (DVAX) shows moderate financial fundamentals with a PE ratio of -41.89, profit margin of -13.13%, and ROE of -8.05%. The company generates $0.3B in annual revenue with strong year-over-year growth of 19.36%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 27.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze DVAX's fundamental strength across five key dimensions:
Efficiency Score
WeakDVAX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentDVAX trades at attractive valuation levels.
Growth Score
ModerateDVAX shows steady but slowing expansion.
Financial Health Score
ExcellentDVAX maintains a strong and stable balance sheet.
Profitability Score
WeakDVAX struggles to sustain strong margins.
Key Financial Metrics
Is DVAX Expensive or Cheap?
P/E Ratio
DVAX trades at -41.89 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, DVAX's PEG of -1.76 indicates potential undervaluation.
Price to Book
The market values Dynavax Technologies Corporation at 3.40 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -66.10 times EBITDA. This is generally considered low.
How Well Does DVAX Make Money?
Net Profit Margin
For every $100 in sales, Dynavax Technologies Corporation keeps $-13.13 as profit after all expenses.
Operating Margin
Core operations generate 3.16 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-8.05 in profit for every $100 of shareholder equity.
ROA
Dynavax Technologies Corporation generates $-4.59 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Dynavax Technologies Corporation generates strong operating cash flow of $90.72M, reflecting robust business health.
Free Cash Flow
Dynavax Technologies Corporation generates strong free cash flow of $80.62M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.69 in free cash annually.
FCF Yield
DVAX converts 4.42% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-41.89
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.76
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.40
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.51
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.53
vs 25 benchmark
Current Ratio
Current assets to current liabilities
7.62
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.08
vs 25 benchmark
ROA
Return on assets percentage
-0.05
vs 25 benchmark
ROCE
Return on capital employed
0.01
vs 25 benchmark
How DVAX Stacks Against Its Sector Peers
| Metric | DVAX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -41.89 | 29.28 | Better (Cheaper) |
| ROE | -8.05% | 820.00% | Weak |
| Net Margin | -13.13% | -19731.00% (disorted) | Weak |
| Debt/Equity | 0.53 | 0.26 | Weak (High Leverage) |
| Current Ratio | 7.62 | 4.69 | Strong Liquidity |
| ROA | -4.59% | -17993.00% (disorted) | Weak |
DVAX outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Dynavax Technologies Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
335.98%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
109.91%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
130.38%
Industry Style: Defensive, Growth, Innovation
High Growth